Citric acid with potassium citrate
Brand names: Cymalon
Citric acid with potassium citrate is an oral urinary alkalinising preparation used to relieve discomfort in lower urinary tract infections and to raise urinary pH, for example to help prevent uric acid or cystine stones.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Citrate is metabolised to bicarbonate, which is excreted in the urine to raise urinary pH; alkalinisation increases the solubility of uric acid and cystine, while citrate also inhibits calcium stone crystallisation.
Prescribing in practice
- The potassium content can cause hyperkalaemia, so use with caution and monitor potassium in chronic kidney disease and in patients on potassium-sparing diuretics, ACE inhibitors or ARBs.
- Avoid in significant renal impairment with hyperkalaemia and in conditions where a sodium or potassium load is hazardous; it is for short-term symptomatic relief unless used for stone prevention.
- Urinary alkalinisation alters renal handling of some drugs and is not a substitute for antibiotics when an infection requires treatment.
Monitoring
Monitor serum potassium and, when used for stone prevention, urinary pH, particularly in renal impairment.
Counselling the patient
- Dissolve or take as directed with plenty of water and keep well hydrated.
- This eases urinary discomfort but does not replace antibiotics if you have an infection that needs them.
- Tell your prescriber if you have kidney problems or take blood-pressure medicines that raise potassium.
Evidence & guidelines
Potassium citrate is an established urinary alkalinising agent used for symptomatic relief in lower urinary tract infection and as part of metabolic stone-prevention regimens.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Hyperkalaemia Management Algorithm · Electrolyte Disorders
- Tumor Lysis Syndrome Risk (Cairo-Bishop) · Oncological Emergency
- FAST Exam Protocol — Focused Assessment with Sonography in Trauma · Trauma
- Urine Anion Gap · Acid-Base
- Transtubular Potassium Gradient (TTKG) · Electrolytes
- Bicarbonate Deficit Calculator · Acid-Base